News

Hemostemix Engages PatentVest to Strengthen its Global Patent Portfolio

  • Calgary, Alberta--(Newsfile Corp. - April 23, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) a leader in the development of autologous stem cell therapy for the treatment of cardiovascular diseases, announces its partnership with PatentVest. PatentVest, a subsidiary of MDB Capital (NASDAQ: MDBH), is a premier intellectual property strategy and patent prosecution firm specializing in life sciences.
    04/23/2025

MDB Capital Holdings, LLC (MDBH) Q4 2024 Earnings Call Transcript

  • MDB Capital Holdings, LLC (NASDAQ:MDBH ) Q4 2024 Earnings Conference Call March 31, 2025 4:30 PM ET Company Participants Kevin Cotter – Managing Director-Investment Banking Chris Marlett – Chief Executive Officer and Co-Founder Jeremy James – Chief Financial Officer Gary Schuman – Broker Dealer Chief Financial Officer and Head-Compliance Conference Call Participants Kevin Cotter [Call Starts Abruptly] will follow the formal presentation. If you have questions during the presentation, you can type them into the chat to be answered during the question-and-answer period.
    04/03/2025
Profitability
Dividends
Income Statement
Balance Sheet
Cash Flow Statement
Symbol Frequently Asked Questions

MDB Capital Holdings, LLC Class A common (MDBH) can buy. Click on Rating Page for detail.

The price of MDB Capital Holdings, LLC Class A common (MDBH) is 4.4 and it was updated on 2025-05-11 01:39:53.

Currently MDB Capital Holdings, LLC Class A common (MDBH) is in undervalued.

News
    
News

New PatentVest Pulse Report Maps the Competitive and IP Landscape of the $400B Brain-Computer Interface (BCI) Market

  • Designed for investors, board members, and CEOs, the latest PatentVest Pulse offers a strategic view of who's winning—and why—in the emerging BCI market Designed for investors, board members, and CEOs, the latest PatentVest Pulse offers a strategic view of who's winning—and why—in the emerging BCI market
    Tue, Apr. 01, 2025

MDB Capital Holdings to Host Fourth Quarter and Full Year 2024 Results Conference Call on Monday March 31, 2025, at 4:30 p.m. Eastern Time

  • Addison, TX, March 24, 2025 (GLOBE NEWSWIRE) -- MDB Capital Holdings, LLC, (NASDAQ: MDBH) (“MDB”), a public venture platform focused on launching category-leading deep technology companies, plans to host a Zoom webinar on Monday March 31, 2025 at 4:30 p.m. Eastern Time to discuss its results for the fourth quarter and full year 2024. A press release detailing these results will be issued prior to the call. Christopher Marlett, CEO and Co-Founder of MDB will lead the call and will be joined by other members of the management team to review recent developments, ongoing initiatives, anticipated milestones, as well as host a question-and-answer period. Investors can pre-register now for the Zoom webinar  HERE . The live webinar can also be accessed on the day of the event through MDB's investor relations website at https://investors.mdb.com/. About MDB Capital Holdings, LLC Founded in 1997, MDB Capital makes investments that can change lives by discovering and transforming deep technology Big Ideas into valuable public companies through a unique approach to public venture capital. This approach focuses on community-driven financings of pre-revenue, early-stage deep technology companies through early initial public offerings (IPOs), primarily listed on NASDAQ, as well as post-IPO offerings for already public companies that fit MDB's overall investment criteria. MDB Capital is the brand under which MDB Capital Holdings, LLC (NASDAQ: MDBH) and its subsidiaries operate and provide services. This includes MDB Capital, a self-clearing broker-dealer with the MDB Direct trading platform, and PatentVest, the first integrated, intellectual property (IP) intelligence, strategy consulting and IP law firm. MDB Capital is a registered broker-dealer, a member of FINRA and a member of SIPC. For more information, please visit www.mdb.com. Forward-Looking Statements This press release contains "forward-looking statements." These forward-looking statements are made as of the date they were first issued and were based on current expectations, estimates, forecasts and projections as well as the beliefs and assumptions of management. Words such as "expect," "anticipate," "should," "believe," "hope," "target," "project," "goals," "estimate," "potential," "predict," "may," "will," "might," "could," "intend," "shall" and variations of these terms or the negative of these terms and similar expressions are intended to identify these forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond MDB's control. MDB's actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including but not limited to, risks detailed in documents that may be filed by MDB from time to time with the SEC. The forward-looking statements included in this press release represent MDB's views as of the date of this press release. MDB anticipates that subsequent events and developments will cause its views to change. MDB undertakes no intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. These forward-looking statements should not be relied upon as representing MDB's views as of any date subsequent to the date of this press release.   Investor Relations Contact: IR@mdb.com   Media Contact: press@mdb.com
    Mon, Mar. 24, 2025

New PatentVest Pulse Report Reveals Transformative Trends in the AI Data Center Patent Race

  • •China accounts for 77% of all AI data center patent filings globally, with five of the top patent holders hailing from China - underlining its dominant position in next-generation AI infrastructure •China accounts for 77% of all AI data center patent filings globally, with five of the top patent holders hailing from China - underlining its dominant position in next-generation AI infrastructure
    Wed, Mar. 05, 2025

eXoZymes Announces Nasdaq Bell Ringing to Commemorate Initial Public Offering

  • Monrovia, CA, Feb. 19, 2025 (GLOBE NEWSWIRE) -- eXoZymes, Inc. (Nasdaq: EXOZ) (“eXoZymes”) – a pioneer of AI-engineered enzymes that can transform sustainable feedstock into essential chemicals, medicines, and biofuels – today announced that CEO Michael Heltzen will be joined by eXoZymes team members to ring the Nasdaq Stock Market (“Nasdaq”) closing bell on Wednesday, February 19, 2025. This comes following a successful initial public offering of common stock at $8 per share, which closed on November 14, 2024.
    Wed, Feb. 19, 2025

Rebranding Invizyne to eXoZymes Signifies a Sustainable Paradigm Shift in Chemical Production Leveraging AI-Engineered Enzymes

  • Rebranding Invizyne Technologies, Inc to eXoZymes Inc. Changing NASDAQ ticker from IZTC to EXOZ Introducing but not trademarking “exozymes” as a new scientific nomenclature Monrovia, California, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Today, Invizyne Technologies, Inc. - a pioneer of AI-engineered enzymes that can sustainably transform feedstock into essential chemicals, medicines, and biofuels, announced a corporate name change to eXoZymes, Inc. (“eXoZymes”) and that its common stock will begin trading on the Nasdaq Capital Market under the new ticker symbol of “EXOZ” effective before the market open. No action is required by existing shareholders with respect to the name and ticker symbol change.
    Wed, Feb. 12, 2025
Transcripts
Transcipts Data
SEC Filings
SEC Filings
Press Releases
StockPrice Release
More Headlines
News

Invizyne Technologies Announces Name Change to eXoZymes, Inc. and New Ticker Symbol

  • Trading Under New Ticker of “EXOZ” Expected to Begin February 12, 2025 Trading Under New Ticker of “EXOZ” Expected to Begin February 12, 2025
  • 02/10/2025

Rethinking Diabetes Care: PatentVest Pulse Unveils Key Insights on the Expanding CGM Market and the Innovations Driving Change

  • Addison, TX, Jan. 07, 2025 (GLOBE NEWSWIRE) -- PatentVest, a leader in intellectual property (IP) intelligence and strategy, has released its latest report, “Continuous Glucose Monitoring (CGM): An Evolving Innovation Landscape.” This in-depth analysis explores the rapidly growing CGM market, offering valuable insights into the trends, key players, and opportunities that are shaping the future of diabetes care.
  • 01/07/2025

MDB Capital Holdings Provides Third Quarter 2024 Update

  • Addison, TX, Nov. 21, 2024 (GLOBE NEWSWIRE) -- MDB Capital Holdings, LLC, (NASDAQ: MDBH) (“MDB”), a public venture platform focused on launching category-leading deep technology companies, today provides an update on operations through and subsequent to the quarter ended September 30, 2024. “Throughout the year, we continued to strengthen our operations to increase our capacity to curate and diligence deep technology ideas that we can ultimately finance and help stand up to become leaders in their technology category,” said Christopher Marlett, CEO and Co-Founder of MDB.
  • 11/21/2024

Invizyne Technologies Selected for $2 Million Project to Advance Sustainable Aviation Fuel Capabilities

  • Project is part of the U.S. Department of Defense's BioMADE initiative to support U.S. bioindustrial manufacturing innovations and workforce development Project is part of the U.S. Department of Defense's BioMADE initiative to support U.S. bioindustrial manufacturing innovations and workforce development
  • 11/19/2024

MDB Capital Holdings to Host Third Quarter 2024 Results Conference Call on Thursday November 21, 2024, at 4:30 p.m. Eastern Time

  • Addison, Texas, Nov. 15, 2024 (GLOBE NEWSWIRE) -- MDB Capital Holdings, LLC, (NASDAQ: MDBH) (“MDB”), a public venture platform focused on launching category-leading deep technology companies, plans to host a Zoom webinar on Thursday November 21, 2024 at 4:30 p.m. Eastern Time to discuss its results for the third quarter 2024. A press release detailing these results will be issued prior to the call.
  • 11/15/2024

Invizyne Technologies Announces Closing of Initial Public Offering

  • Monrovia, CA, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Invizyne Technologies, Inc. , a leading designer of cell-free, enzyme-based biomanufacturing systems to produce commercially important molecules and chemicals for everyday life, today announced the closing of its initial public offering of 1,875,000 shares of its common stock at a public offering price of $8.00 per share. The shares began trading on NASDAQ under the ticker symbol “IZTC” on November 13, 2024.
  • 11/14/2024

Invizyne's Nasdaq IPO Marks New Era of Biomanufacturing

  • Underlying technology demonstrates the use of enhanced enzyme systems outside of cells can bypass many of the limitations associated with traditional cell-based synthetic biology Underlying technology demonstrates the use of enhanced enzyme systems outside of cells can bypass many of the limitations associated with traditional cell-based synthetic biology
  • 11/13/2024

Invizyne Technologies Begins Trading on NASDAQ

  • Next Generation Synthetic Biology Company Will Trade Under Ticker Symbol "IZTC" Next Generation Synthetic Biology Company Will Trade Under Ticker Symbol "IZTC"
  • 11/13/2024

Invizyne Technologies to Begin Trading on NASDAQ on November 13, 2024

  • Next Generation Synthetic Biology Company Will Trade Under Ticker Symbol "IZTC" Next Generation Synthetic Biology Company Will Trade Under Ticker Symbol "IZTC"
  • 11/12/2024

Invizyne Technologies Announces Pricing of $15 Million Initial Public Offering

  • Shares to Begin Trading on NASDAQ on November 12, 2024, Under the Ticker Symbol “IZTC” Shares to Begin Trading on NASDAQ on November 12, 2024, Under the Ticker Symbol “IZTC”
  • 11/11/2024

MDB Capital Announces Record Date and Expected Timing for Initial Public Offering for Invizyne Technologies

  • Record date of July 22, 2024 set for allocation preferences Closing and trading expected on NASDAQ on or before August 15 Addison, Texas, July 11, 2024 (GLOBE NEWSWIRE) -- MDB Capital Holdings, LLC, (NASDAQ: MDBH) (“MDB”), a public venture platform focused on launching category-leading deep technology companies, today announces the record date, allocation preference, and expected timeline for the proposed offering for Invizyne Technologies, Inc. In February 2024, Invizyne ­– a leading designer of cell-free, enzyme-based biomanufacturing systems to produce commercially important molecules and chemicals for everyday life and a subsidiary of MDB Capital Holdings – filed its IPO registration statement on Form S-1 with the U.S. Securities and Exchange Commission ("SEC") for the sale of its common stock in a firm commitment public offering. The offering will be for 4,300,000 shares of common stock at a price per share of $4.00, for gross proceeds of $17.2 million.
  • 07/11/2024

Recently Published Whitepaper from PatentVest Delves into Transformative Innovations in MASH Diagnostics

  • Transformative Innovations in MASH Diagnostics Dallas, Texas, July 09, 2024 (GLOBE NEWSWIRE) -- PatentVest, the first integrated IP intelligence strategy and law firm, recently published a whitepaper that presents strategic insights in the fields of Metabolic-Associated Steatohepatitis (MASH) biomarkers and Point of Care (PoC) kits for MASH diagnostics. This whitepaper serves as a valuable resource for stakeholders looking to navigate the complex and rapidly evolving landscape of these fields, offering guidance on capitalizing on innovation, collaboration, and IP protection to gain a competitive edge.
  • 07/09/2024

MDB Capital Collaborates with Mayo Clinic to Advance Anti-Senescence Platform

  • ADDISON, Texas, July 08, 2024 (GLOBE NEWSWIRE) -- MDB Capital Holdings, LLC, (NASDAQ: MDBH) (“MDB”), a public venture platform focused on launching category-leading deep technology companies, today announced a collaboration through a patent and know-how agreement with Mayo Clinic to develop a small molecule anti-senescence platform. This collaboration aims to advance research in longevity and age-related disease prevention.
  • 07/08/2024

MDB Capital Expands Board, Appoints Daniel Torpey as New Director

  • Addison, Texas, June 20, 2024 (GLOBE NEWSWIRE) -- MDB Capital Holdings, LLC, (NASDAQ: MDBH) (“MDB Capital”), a public venture platform focused on launching category-leading deep technology companies, today announced the appointment of Daniel Torpey to its Board of Directors, effective June 17, 2024.
  • 06/20/2024

New PatentVest Pulse Report Reveals Transformative Trends in Portable ECG Monitoring

  • 56% increase in global patent publications over the last five years signals growing interest in the cardiac monitoring market which is expected to grow to $3 billion per year by 2029 according to Statista. PatentVest's report provides groundbreaking insights into the evolving landscape of cardiac care, highlighting key players, technological advancements and the race for innovation.
  • 05/22/2024

MDB Capital Holdings Unveils Unified Corporate Branding

  • Addison, TX, May 22, 2024 (GLOBE NEWSWIRE) -- MDB Capital Holdings, LLC, (NASDAQ: MDBH) (“MDB”), a public venture platform focused on launching category-leading deep technology companies, today announces its self-clearing broker dealer and associated online and mobile trading platforms will now unify under one brand name, MDB Capital.
  • 05/22/2024

Invizyne Technologies Expands Leadership Team Ahead of Proposed Offering and Listing on Nasdaq

  • Michael Heltzen appointed as CEO bringing 20 years of global commercial leadership experience and a track record of successful launches and exits Additional industry veterans join in key roles including business development, finance, and communications MONROVIA, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Invizyne Technologies, Inc. , a leading designer of cell-free, enzyme-based biomanufacturing systems to produce commercially important molecules and chemicals for everyday life, today announced the appointment of Michael Heltzen as CEO, and the recent hirings of additional seasoned industry executives for its leadership team.
  • 05/07/2024

Invizyne Technologies Expands Leadership Team Ahead of Proposed Offering and Listing on Nasdaq

  • MONROVIA, Calif., May 07, 2024 (GLOBE NEWSWIRE) --   Invizyne Technologies, Inc. , a leading designer of cell-free, enzyme-based biomanufacturing systems to produce commercially important molecules and chemicals for everyday life, today announced the appointment of Michael Heltzen as CEO, and the recent hirings of additional seasoned industry executives for its leadership team.
  • 05/07/2024

MDB Capital Holdings Year-End Update

  • Addison, Texas, April 17, 2024 (GLOBE NEWSWIRE) -- MDB Capital Holdings, LLC, (NASDAQ: MDBH) (“MDB”), a public venture platform focused on launching category-leading deep technology companies, reported results for its fourth quarter and full year ended December 31, 2023, on form 10-K filed with the Securities and Exchange Commission, and will highlight recent corporate progress on today's call with management. “On the heels of completing our IPO on the NASDAQ in the third quarter of 2023, we've been working diligently to advance our self-clearing broker dealer capabilities to support our investor community, increasing the number of deep technology ideas we review and ultimately finance, as well as ramp up the number of clients engaged with our integrated IP solution platform, PatentVest, which is critical in assisting the companies we back to become leaders in their technology category,” said Christopher Marlett, CEO and Co-Founder of MDB.
  • 04/17/2024

MDB Capital Holdings to Host Fourth Quarter 2023 and Fiscal

  • Addison, Texas, April 11, 2024 (GLOBE NEWSWIRE) — MDB Capital Holdings, LLC, (NASDAQ: MDBH) (“MDB”), a public venture platform with the objective of growing the public venture marketplace and optimizing the way meaningful technologies are financed and built, plans to host a Zoom webinar on Wednesday April 17, 2024 at 4:30 p.m. Eastern Time to … The post MDB Capital Holdings to Host Fourth Quarter 2023 and Fiscal appeared first on Headlines of Today...
  • 04/11/2024

MDB Capital Holdings to Host Fourth Quarter 2023 and Fiscal Year 2023 Results Webinar on Wednesday April 17, 2024 at 4:30 PM Eastern Time

  • Addison, Texas, April 11, 2024 (GLOBE NEWSWIRE) -- MDB Capital Holdings, LLC, (NASDAQ: MDBH) (“MDB”), a public venture platform with the objective of growing the public venture marketplace and optimizing the way meaningful technologies are financed and built, plans to host a Zoom webinar on Wednesday April 17, 2024 at 4:30 p.m. Eastern Time to discuss its results for the fourth quarter and full fiscal year ended December 31, 2023. A press release detailing these results will be issued prior to the call.
  • 04/11/2024

MDB Capital Holdings Issues Annual Letter to Shareholders

  • Addison, TX, Jan. 31, 2024 (GLOBE NEWSWIRE) -- MDB Capital Holdings, LLC, (NASDAQ: MDBH) (“MDB”), a public venture platform with the objective of growing the public venture marketplace and optimizing the way meaningful technologies are financed and built, today released its annual letter to shareholders from its CEO and Co-Founder, Christopher Marlett.
  • 01/31/2024

MDB Capital Holdings Reports Third Quarter 2023 Results

  • Addison, TX, Nov. 15, 2023 (GLOBE NEWSWIRE) -- MDB Capital Holdings, LLC, (NASDAQ: MDBH) (“MDB”), a public venture platform with the objective of growing the public venture marketplace and optimizing the way meaningful technologies are financed and built, yesterday reported results for its third quarter ended September 30, 2023 on form 10-Q filed with the Securities and Exchange Commission, and will highlight recent corporate progress on today's call with management.
  • 11/15/2023

Michael Burns Joins Invizyne as Executive Vice President of Energy Transition

  • Monrovia, CA, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Invizyne Technologies, Inc. , a leading designer of enzyme-based biomanufacturing systems – and a subsidiary of  MDB Capital Holdings, LLC , (NASDAQ:MDBH) ("MDB") ­– today announced the appointment of Michael Burns to its senior leadership team as Executive Vice President, Energy Transition.
  • 11/08/2023

Invizyne Selected by Shell GameChanger Accelerator Powered by NREL for Sixth Cohort

  • Non-Dilutive Funding and Resources Provided to De-Risk Investment and Accelerate Commercialization Non-Dilutive Funding and Resources Provided to De-Risk Investment and Accelerate Commercialization
  • 10/17/2023

Invizyne Awarded Additional $3.77 Million Grant from U.S. Department of Energy

  • Funding Supports Project to Optimize and Scale Up Isobutanol Production to Address Potential $27.4 Billion Sustainable Aviation Fuel Market Funding Supports Project to Optimize and Scale Up Isobutanol Production to Address Potential $27.4 Billion Sustainable Aviation Fuel Market
  • 10/11/2023

MDB Capital Holdings Begins Trading on NASDAQ

  • Public Venture Platform Company Will Trade Under Ticker Symbol "MDBH" ADDISON, TX / ACCESSWIRE / September 21, 2023 / MDB Capital Holdings, LLC, (NASDAQ:MDBH) ("MDB") a public venture platform with the objective of growing the public venture marketplace and optimizing the way meaningful technologies are financed and built, today announced it raised $19,999,992 and is pleased to announce that its Class A Common Shares representing MDB limited liability interests will begin trading on the NASDAQ today, September 21, 2023 at approximately 10:45am EST under the ticker symbol "MDBH." About MDB Capital Holdings, LLC MDB was founded in 1997 with the purpose of backing visionary technology, inventors, and technology entrepreneurs via a new form of public venture capital that finances pre-revenue, early-stage companies through early public offerings, primarily listed on NASDAQ.
  • 09/21/2023
Unlock
MDBH Ratings Summary
MDBH Quant Ranking